|
| All | Prophylactic Groups | p-Value* | Subgroups | p-Value* | |||
| Amiodarone | Placebo | POAF | NO POAF | |||||
| Characteristics |
|
|
|
|
|
|
| |
| N (%) | 196 (100) | 94 (48) | 102 (52) | N/A | 45 (23) | 151 (77) | N/A | |
| Age (median, IQR) | 65 (59; 71) | 66 (60; 72) | 65 (58; 70) | 0.605 | 69 (64; 74) | 64 (57; 70) | 0.001* | |
| Sex (male, n (%)) | 166 (85) | 83 (88) | 83 (81) | 0.179 | 40 (89) | 126 (83) | 0.373 | |
| Current smoker (n (%)) | 51 (26) | 26 (28) | 25 (25) | 0.616 | 12 (27) | 39 (26) | 0.910 | |
| Diabetes mellitus (n (%)) | 48 (25) | 23 (25) | 25 (25) | 0.995 | 13 (29) | 35 (23) | 0.434 | |
| Hypertension (n (%)) | 127 (65) | 61 (65) | 66 (65) | 0.978 | 28 (62) | 99 (66) | 0.680 | |
| Hypercholesterolemia (n (%)) | 136 (69) | 64 (68) | 72 (71) | 0.704 | 27 (60) | 109 (72) | 0.120 | |
| Family history of IHD (n (%)) | 93 (47) | 41 (48) | 52 (57) | 0.238 | 17 (45) | 76 (54) | 0.296 | |
| History of CNS events (n (%)) | 46 (24) | 21 (23) | 25 (28) | 0.414 | 12 (31) | 34 (24) | 0.413 | |
| COPD (n (%)) | 13 (7) | 9 (10) | 4 (4) | 0.112 | 6 (13) | 7 (5) | 0.079 | |
| NYHA Class (n (%)) |
|
|
|
|
|
|
| |
|
| NYHA Class I | 56 (29) | 27 (29) | 29 (28) | 0.964 | 12 (27) | 44 (29) | 0.747 |
|
| NYHA Class II | 92 (50) | 44 (47) | 48 (47) | 0.972 | 17 (38) | 75(50) | 0.161 |
|
| NYHA Class III | 46 (24) | 23 (25) | 23 (23) | 0.751 | 15 (33) | 31 (21) | 0.075 |
|
| NYHA Class IV | ** | ** | ** | 0.498 | ** | ** | 0.407 |
| CCS Class (n (%)) |
|
|
|
|
|
|
| |
|
| CCS Class I | 40 (20) | 19 (20) | 21 (21) | 0.948 | 13 (29) | 27 (18) | 0.108 |
|
| CCS Class II | 94 (48) | 47 (46) | 47 (50) | 0.583 | 17 (38) | 77 (51) | 0.119 |
|
| CCS Class III | 49 (25) | 21 (22) | 28 (28) | 0.409 | 12 (27) | 37 (25) | 0.769 |
|
| CCS Class IV | 13 (7) | 7 (7) | 6 (6) | 0.660 | ** | 10 (7) | 1.000 |
| Previous MI (n (%)) | 93 (47) | 45 (48) | 48 (47) | 0.909 | 18 (40) | 75 (50) | 0.254 | |
| Previous PCI (n (%)) | 17 (9) | 7 (7) | 10 (10) | 0.558 | ** | 15 (10) | 0.369 | |
| Preoperative use of β-blockers (n (%)) | 170 (87) | 81 (86) | 89 (87) | 0.823 | 38 (84) | 132 (87) | 0.606 | |
| Preoperative use of statins (n (%)) | 173 (88) | 81 (86) | 92 (90) | 0.382 | 38 (84) | 135 (89) | 0.364 | |
| EF (median, IQR) | 56 (49; 60) | 55 (48; 60) | 56 (50; 60) | 0.857 | 56 (45; 60) | 57 (50; 60) | 0.392 | |
| Creatinine (μmol/L) (median, IQR) | 88 (75; 99) | 89 (75; 99) | 87 (76; 99) | 0.818 | 91 (79; 106) | 88 (75; 98) | 0.106 | |
| BMI (mean, SD) | 27.52 (4.14) | 27.50 (4.06) | 27.54 (4.23) | 0.943 | 28.24 (4.37) | 27.30 (4.06) | 0.184 | |
| EuroSCORE I (median, IQR) | 2 (1; 4) | 3 (1; 4) | 2 (1; 4) | 0.210 | 3 (2; 5) | 2 (1; 4) | 0.009* | |
| Vessels affected (No. (n (%)) |
|
|
|
|
|
|
| |
|
| 1 | ** | ** | ** | 0.498 | ** | ** | 0.407 |
|
| 2 | 20 (10) | 6 (6) | 14 (14) | 0.090 | 6 (13) | 14 (9) | 0.429 |
|
| 3 | 174 (89) | 88 (94) | 86 (84) | 0.039* | 38 (84) | 136 (90) | 0.294 |
| Lesion location (n (%)) |
|
|
|
|
|
|
| |
|
| Left main stenosis | 78 (40) | 36 (38) | 42 (41) | 0.770 | 26 (58) | 52 (34) | 0.005* |